Barclays PLC Has $884,000 Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Barclays PLC grew its position in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) by 200.5% during the third quarter, HoldingsChannel.com reports. The firm owned 37,625 shares of the company’s stock after purchasing an additional 25,106 shares during the period. Barclays PLC’s holdings in Tyra Biosciences were worth $884,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. HighVista Strategies LLC acquired a new position in Tyra Biosciences during the 2nd quarter worth about $257,000. Valence8 US LP bought a new stake in Tyra Biosciences in the third quarter valued at approximately $310,000. SG Americas Securities LLC acquired a new stake in Tyra Biosciences during the 3rd quarter valued at approximately $311,000. The Manufacturers Life Insurance Company bought a new position in Tyra Biosciences during the 3rd quarter worth approximately $333,000. Finally, Rhumbline Advisers boosted its stake in shares of Tyra Biosciences by 12.3% in the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after purchasing an additional 2,574 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Insider Buying and Selling at Tyra Biosciences

In other news, CFO Alan Fuhrman acquired 9,500 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the purchase, the chief financial officer now owns 12,849 shares in the company, valued at approximately $205,584. This represents a 283.67 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Nina S. Kjellson sold 27,493 shares of Tyra Biosciences stock in a transaction on Friday, November 1st. The stock was sold at an average price of $16.56, for a total value of $455,284.08. Following the sale, the director now owns 458,506 shares in the company, valued at $7,592,859.36. This trade represents a 5.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 74,125 shares of company stock worth $1,583,097. Insiders own 15.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Wedbush reissued an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $22.00 to $31.00 in a research report on Friday, October 18th. Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. UBS Group started coverage on Tyra Biosciences in a report on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Monday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tyra Biosciences currently has a consensus rating of “Buy” and a consensus price target of $30.50.

Tyra Biosciences Stock Up 5.6 %

NASDAQ TYRA opened at $15.94 on Wednesday. Tyra Biosciences, Inc. has a 52 week low of $12.17 and a 52 week high of $29.60. The business has a 50 day moving average price of $15.40 and a 200-day moving average price of $19.22. The company has a market cap of $806.61 million, a price-to-earnings ratio of -9.90 and a beta of 1.04.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). On average, equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.